Skip Nav Destination
Issues
1 November 2023
-
Cover Image
Cover Image
Image captured by the NanoString GeoMx Digital Spatial Profiler showing a tissue section of normal colorectal mucosa of a Lynch Syndrome carrier. Immunofluorescence staining demonstrates the infiltration by CD45+ immune cells (red) and CD8+ T cells (yellow). For details, see the article by Deng and colleagues on page 4361 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer
Sandra J. Casak; M. Naomi Horiba; Mengdie Yuan; Joyce Cheng; Steven J. Lemery; Yuan Li Shen; Wentao Fu; Jason N. Moore; Yangbing Li; Youwei Bi; Doris Auth; Nataliya Fesenko; Paul G. Kluetz; Richard Pazdur; Lola A. Fashoyin-Aje
Perspective
Clinical Trials: Targeted Therapy
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Michela Casanova; Francisco Bautista; Quentin Campbell-Hewson; Guy Makin; Lynley V. Marshall; Arnauld C. Verschuur; Adela Cañete Nieto; Nadège Corradini; Bart A. Ploeger; Barbara J. Brennan; Udo Mueller; Hong Zebger-Gong; John W. Chung; Birgit Geoerger
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Jayastu Senapati; Warren C. Fiskus; Naval Daver; Nathaniel R. Wilson; Farhad Ravandi; Guillermo Garcia-Manero; Tapan Kadia; Courtney D. DiNardo; Elias Jabbour; Jan Burger; Nicholas J. Short; Yesid Alvarado; Nitin Jain; Lucia Masarova; Ghayas C. Issa; Wei Qiao; Joseph D. Khoury; Sherry Pierce; Darla Miller; Koji Sasaki; Marina Konopleva; Kapil N. Bhalla; Gautam Borthakur; Naveen Pemmaraju
Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Nan Deng; Laura Reyes-Uribe; Johannes F. Fahrmann; Whittney S. Thoman; Mark F. Munsell; Jennifer B. Dennison; Eunice Murage; Ranran Wu; Ernest T. Hawk; Selvi Thirumurthi; Patrick M. Lynch; Christina M. Dieli-Conwright; Alexander J. Lazar; Sonali Jindal; Khoi Chu; Manoj Chelvanambi; Karen Basen-Engquist; Yisheng Li; Jennifer A. Wargo; Florencia McAllister; James P. Allison; Padmanee Sharma; Krishna M. Sinha; Samir Hanash; Susan C. Gilchrist; Eduardo Vilar
Clinical Trials: Immunotherapy
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Alexandra Drakaki; Thomas Powles; Aristotelis Bamias; Juan Martin-Liberal; Sang Joon Shin; Terence Friedlander; Diego Tosi; Chandler Park; Carlos Gomez-Roca; Florence Joly Lobbedez; Daniel Castellano; Rafael Morales-Barrera; Irene Moreno-Candilejo; Aude Fléchon; Kobe Yuen; Deepali Rishipathak; Kelly DuPree; Fiona Young; Francesca Michielin; Colby S. Shemesh; Elizabeth E. Steinberg; Patrick Williams; Jae Lyun Lee
Precision Medicine and Imaging
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Timothy P. DiPeri; Kurt W. Evans; Maria Gabriela Raso; Ming Zhao; Yasmeen Q. Rizvi; Xiaofeng Zheng; Bailiang Wang; Bryce P. Kirby; Kathleen Kong; Michael Kahle; Timothy A. Yap; Ecaterina E. Dumbrava; Jaffer A. Ajani; Siqing Fu; Khandan Keyomarsi; Funda Meric-Bernstam
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Connor J. Kinslow; Ali I. Rae; Kekoa Taparra; Prashanth Kumar; Markus D. Siegelin; Jack Grinband; Brian J.A. Gill; Guy M. McKhann; Michael B. Sisti; Jeffrey N. Bruce; Peter D. Canoll; Fabio M. Iwamoto; David P. Horowitz; Lisa A. Kachnic; Alfred I. Neugut; James B. Yu; Simon K. Cheng; Tony J.C. Wang
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Rohit Thummalapalli; Biagio Ricciuti; Chaitanya Bandlamudi; Daniel Muldoon; Hira Rizvi; Arielle Elkrief; Jia Luo; Joao V. Alessi; Federica Pecci; Giuseppe Lamberti; Alessandro Di Federico; Lingzhi Hong; Jianjun Zhang; John V. Heymach; Don L. Gibbons; Andrew J. Plodkowski; Vignesh Ravichandran; Mark T.A. Donoghue; Chad Vanderbilt; Marc Ladanyi; Charles M. Rudin; Mark G. Kris; Gregory J. Riely; Jamie E. Chaft; Matthew D. Hellmann; Natalie I. Vokes; Mark M. Awad; Adam J. Schoenfeld
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Raphaël Leman; Etienne Muller; Angelina Legros; Nicolas Goardon; Imène Chentli; Alexandre Atkinson; Aurore Tranchant; Laurent Castera; Sophie Krieger; Agathe Ricou; Flavie Boulouard; Florence Joly; Romain Boucly; Aurélie Dumont; Noémie Basset; Florence Coulet; Louise-Marie Chevalier; Etienne Rouleau; Katharina Leitner; Antonio González-Martin; Piera Gargiulo; Hans-Joachim Lück; Catherine Genestie; the PAOLA-1 investigators; Isabelle Ray-Coquard; Eric Pujade-Lauraine; Dominique Vaur
Circulating microRNAs and Cytokines as Prognostic Biomarkers for Doxorubicin-Induced Cardiac Injury and for Evaluating the Effectiveness of an Exercise Intervention
Prince Jeyabal; Anchit Bhagat; Fei Wang; Michael Roth; J. Andrew Livingston; Susan C. Gilchrist; Jose Banchs; Michelle A.T. Hildebrandt; Joya Chandra; Anita Deswal; Efstratios Koutroumpakis; Jian Wang; Najat C. Daw; Theresa A. Honey; Eugenie S. Kleinerman
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party
Ali Bazarbachi; Myriam Labopin; Tobias Gedde-Dahl; Peter Remenyi; Edouard Forcade; Nicolaus Kröger; Gerard Socié; Charles Craddock; Jean Henri Bourhis; Jurjen Versluis; Ibrahim Yakoub-Agha; Urpu Salmenniemi; Jean El-Cheikh; Gesine Bug; Jordi Esteve; Arnon Nagler; Fabio Ciceri; Mohamad Mohty
Translational Cancer Mechanisms and Therapy
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Gabrielle Leclercq-Cohen; Nathalie Steinhoff; Llucia Albertí Servera; Sina Nassiri; Sabrina Danilin; Emily Piccione; Emilio Yángüez; Tamara Hüsser; Sylvia Herter; Stephan Schmeing; Petra Gerber; Petra Schwalie; Johannes Sam; Stefanie Briner; Sylvia Jenni; Roberta Bianchi; Marlene Biehl; Floriana Cremasco; Katerina Apostolopoulou; Hélène Haegel; Christian Klein; Pablo Umaña; Marina Bacac
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
Chuandong Geng; Man-Chao Zhang; Ganiraju C. Manyam; Jody V. Vykoukal; Johannes F. Fahrmann; Shan Peng; Cheng Wu; Sanghee Park; Shakuntala Kondraganti; Daoqi Wang; Brian D. Robinson; Massimo Loda; Christopher E. Barbieri; Timothy A. Yap; Paul G. Corn; Samir Hanash; Bradley M. Broom; Patrick G. Pilié; Timothy C. Thompson
Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Grace B. McKay-Corkum; Victor J. Collins; Choh Yeung; Takeshi Ito; Sameer H. Issaq; David Holland; Ksenia Vulikh; Yiping Zhang; Unsun Lee; Haiyan Lei; Arnulfo Mendoza; Jack F. Shern; Marielle E. Yohe; Kazutoshi Yamamoto; Kelli Wilson; Jiuping Ji; Baktiar O. Karim; Craig J. Thomas; Murali C. Krishna; Leonard M. Neckers; Christine M. Heske
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Naoual Menssouri; Loïc Poiraudeau; Carole Helissey; Ludovic Bigot; Jonathan Sabio; Tony Ibrahim; Cédric Pobel; Claudio Nicotra; Maud Ngo-Camus; Ludovic Lacroix; Etienne Rouleau; Lambros Tselikas; Anne Chauchereau; Félix Blanc-Durand; Alice Bernard-Tessier; Anna Patrikidou; Natacha Naoun; Ronan Flippot; Emeline Colomba; Alina Fuerea; Laurence Albiges; Pernelle Lavaud; Paul van de Wiel; Eveline den Biezen; Yvonne Wesseling-Rozendaal; Santiago Ponce; Stefan Michiels; Christophe Massard; Daniel Gautheret; Fabrice Barlesi; Fabrice André; Benjamin Besse; Jean-Yves Scoazec; Luc Friboulet; Karim Fizazi; Yohann Loriot
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds